Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection

Floriane Gallais, Pierre Gantner, Timothée Bruel, Aurelie Velay, Delphine Planas, Marie-Josée Wendling, Sophie Bayer, Morgane Solis, Elodie Laugel, Nathalie Reix, Anne Schneider, Ludovic Glady, Baptiste Panaget, Nicolas Collongues, Marialuisa Partisani, Jean-Marc Lessinger, Arnaud Fontanet, David Rey, Yves Hansmann, Laurence Kling-Pillitteri, Olivier Schwartz, Jérome De Sèze, Nicolas Meyer, Maria Gonzalez, Catherine Schmidt-Mutter, Samira Fafi-Kremer
doi: https://doi.org/10.1101/2021.05.07.21256823
Floriane Gallais
1Virology Laboratory, Strasbourg University Hospital, Strasbourg, France
2Strasbourg University, INSERM, IRM UMR-S 1109, F-67000 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Gantner
1Virology Laboratory, Strasbourg University Hospital, Strasbourg, France
2Strasbourg University, INSERM, IRM UMR-S 1109, F-67000 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothée Bruel
3Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France
4CNRS UMR 3569, Paris, France
5Vaccine Research Institute, Creteil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurelie Velay
1Virology Laboratory, Strasbourg University Hospital, Strasbourg, France
2Strasbourg University, INSERM, IRM UMR-S 1109, F-67000 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Delphine Planas
3Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France
4CNRS UMR 3569, Paris, France
5Vaccine Research Institute, Creteil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Josée Wendling
1Virology Laboratory, Strasbourg University Hospital, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Bayer
6CHU de Strasbourg, Laboratoire de Biochimie Clinique et Biologie Moléculaire, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morgane Solis
1Virology Laboratory, Strasbourg University Hospital, Strasbourg, France
2Strasbourg University, INSERM, IRM UMR-S 1109, F-67000 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elodie Laugel
1Virology Laboratory, Strasbourg University Hospital, Strasbourg, France
2Strasbourg University, INSERM, IRM UMR-S 1109, F-67000 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Reix
6CHU de Strasbourg, Laboratoire de Biochimie Clinique et Biologie Moléculaire, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Schneider
7CHU de Strasbourg, Département de Génétique Moléculaire du cancer, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludovic Glady
6CHU de Strasbourg, Laboratoire de Biochimie Clinique et Biologie Moléculaire, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baptiste Panaget
1Virology Laboratory, Strasbourg University Hospital, Strasbourg, France
2Strasbourg University, INSERM, IRM UMR-S 1109, F-67000 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Collongues
8Centre d’investigation Clinique INSERM 1434, CHU Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marialuisa Partisani
9CHU de Strasbourg, Trait d’Union, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Marc Lessinger
6CHU de Strasbourg, Laboratoire de Biochimie Clinique et Biologie Moléculaire, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnaud Fontanet
10Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France
11PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Rey
9CHU de Strasbourg, Trait d’Union, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Hansmann
12CHU de Strasbourg, Service des infectieuses et tropicales, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence Kling-Pillitteri
13CHU de Strasbourg, Service de Pathologies Professionnelles, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Schwartz
3Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France
4CNRS UMR 3569, Paris, France
5Vaccine Research Institute, Creteil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jérome De Sèze
8Centre d’investigation Clinique INSERM 1434, CHU Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Meyer
14CHU de Strasbourg, Service de santé Publique, GMRC, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Gonzalez
12CHU de Strasbourg, Service des infectieuses et tropicales, F-67091 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Schmidt-Mutter
8Centre d’investigation Clinique INSERM 1434, CHU Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samira Fafi-Kremer
1Virology Laboratory, Strasbourg University Hospital, Strasbourg, France
2Strasbourg University, INSERM, IRM UMR-S 1109, F-67000 Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: samira.fafi-kremer@unistra.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting protection against reinfection and durability of vaccine protection. Here, we longitudinally measured Spike (S) and Nucleocapsid (N)-specific antibodies in 1,309 healthcare workers (HCWs), including 916 COVID-19 negative HCWs and 393 convalescent COVID-19 for up to 422 days post-symptom. From month (M)1 to M7-9 post-infection, SARS-CoV-2 antibodies decreased moderately in convalescent HCWs in a biphasic model, with men showing a slower decay of anti-N (p=0.02), and a faster decay of anti-S (p=0.0008) than women. At M11-13, anti-N dramatically decreased (half-life: 283 days) while anti-S stabilized (half-life: 725 days) at a median of 2.39 log Arbitrary Units (AU)/mL (Interquartile Range (IQR): 2.10 -2.75). Overall, 69 SARS-CoV-2 infections developed in the COVID-19 negative group (incidence of 12.22 per 100 person-years) versus one in the COVID-19 positive group (incidence of 0.40 per 100 person-years), indicating a relative reduction in the incidence of SARS-CoV-2 reinfection of 96.7% (p<0.0001). Correlation with live-virus neutralization assay revealed that variants D614G and B.1.1.7, but not B.1.351, were sensitive to anti-S antibodies at 2.3 log AU/mL, while IgG ≥ 3 log AU/mL neutralized all three variants. After SARS-CoV-2 vaccination, anti-S levels reached at least 3 logs regardless of pre-vaccination IgG levels, type of vaccine, and number of doses. Our study demonstrates a long-term persistence of anti-S IgG antibodies that may protect against reinfection. By significantly increasing cross-neutralizing antibody titers, a single-dose vaccination strengthens protection against escape mutants.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ClinicalTrials.gov Identifier: NCT04441684

Funding Statement

This work was supported by Strasbourg University Hospitals (SeroCoV-HUS; PRI 7782), the Agence Nationale de la Recherche (ANR-18-CE17-0028), Laboratoire d'Excellence TRANSPLANTEX (ANR-11-LABX-0070_TRANSPLANTEX), and Institut National de la Sante et de la Recherche Medicale (UMR_S 1109).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

CPP Sud-Mediterranee 3, CHU de Nimes, Place du Professeur Robert Debre, 30029 Nimes Cedex 9 reference: 2020.04.15 bis_ 20.04.10.66856

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The authors have declared that no conflict of interest exists.

  • Correction of typos in the abstract and in the main text

Data Availability

All data are available upon request to the corresponding author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 17, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection
Floriane Gallais, Pierre Gantner, Timothée Bruel, Aurelie Velay, Delphine Planas, Marie-Josée Wendling, Sophie Bayer, Morgane Solis, Elodie Laugel, Nathalie Reix, Anne Schneider, Ludovic Glady, Baptiste Panaget, Nicolas Collongues, Marialuisa Partisani, Jean-Marc Lessinger, Arnaud Fontanet, David Rey, Yves Hansmann, Laurence Kling-Pillitteri, Olivier Schwartz, Jérome De Sèze, Nicolas Meyer, Maria Gonzalez, Catherine Schmidt-Mutter, Samira Fafi-Kremer
medRxiv 2021.05.07.21256823; doi: https://doi.org/10.1101/2021.05.07.21256823
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection
Floriane Gallais, Pierre Gantner, Timothée Bruel, Aurelie Velay, Delphine Planas, Marie-Josée Wendling, Sophie Bayer, Morgane Solis, Elodie Laugel, Nathalie Reix, Anne Schneider, Ludovic Glady, Baptiste Panaget, Nicolas Collongues, Marialuisa Partisani, Jean-Marc Lessinger, Arnaud Fontanet, David Rey, Yves Hansmann, Laurence Kling-Pillitteri, Olivier Schwartz, Jérome De Sèze, Nicolas Meyer, Maria Gonzalez, Catherine Schmidt-Mutter, Samira Fafi-Kremer
medRxiv 2021.05.07.21256823; doi: https://doi.org/10.1101/2021.05.07.21256823

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (240)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1420)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
  • Epidemiology (10297)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2629)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1733)
  • Health Policy (789)
  • Health Systems and Quality Improvement (673)
  • Hematology (266)
  • HIV/AIDS (565)
  • Infectious Diseases (except HIV/AIDS) (12093)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (289)
  • Neurology (2461)
  • Nursing (145)
  • Nutrition (377)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1324)
  • Ophthalmology (401)
  • Orthopedics (146)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (780)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2397)
  • Public and Global Health (5007)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (528)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (245)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)